Trial Profile
The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 09 Apr 2022
Price :
$35
*
At a glance
- Drugs Remdesivir (Primary) ; Hydroxychloroquine
- Indications SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms N-ReCOVID 19; NOR-SOLIDARITY; S-ReCOVID 19
- 13 Jul 2021 Results (n=185) published in the Annals of Internal Medicine
- 15 Jan 2021 This trial has been discontinued in Sweden, according to European Clinical Trials Database record.
- 08 Jun 2020 Protocol has been amended to remove Hydroxychloroquine as a treatment group after advice from the steering committee because of lack of evidence of its effectiveness, confirmed in both internal WHO interim analyses and an external report from the RECOVERY study